Hanson, Shimadzu combine technologies to create an automated testing system

By Staff reporter

- Last updated on GMT

Hanson, Shimadzu combine techs to create an automated testing system

Related tags Chromatography High performance liquid chromatography

Hanson Research and Shimadzu have teamed up to combine their respective technologies into an automated online pharmaceutical testing system.

The alliance is focused on the integration of Hanson’s semi-automated Vision dissolution platform with Shimadzu’s UV-1800 spectrophotometer. Integrating the UV-1800 into Hanson’s workflow will eliminate the need for users to take dissolution samples offline for UV testing. 

By replacing this manual step with a system that automatically moves samples into flow cells for UV testing, the partners hope to create an online system that meets growing customer demand for automated technologies. Hanson is optimistic about the prospects of the product.

We anticipate strong sales in all of our worldwide regions not only because of the new product itself but also because of the combined strengths of the Shimadzu and Hanson brands​,” Sara Hanson, director of marketing at Hanson, told this publication.

The optimism is underpinned by a belief that pharma testing operations see value in having a unified platform for the whole dissolution process, rather than separate technologies for each task.

Laboratories with an interest in realising efficiencies through automation, improving their reporting and data integrity, achieving security compliance that will stand up to audits and simplifying their operations are being targeted by Shimadzu and Hanson as potential buyers of the product.

The partners are also working to serve dissolution laboratories that need a high-performance liquid chromatography (HPLC) finish. For these customers, Hanson will pair its Vision AutoPlus dissolution autosampler to Shimadzu’s HPLC product. The partners are touting the product as a way to cut the risk of human error and make testing less time consuming for analysts. 

Building business

Shimadzu and Hanson are unveiling the product at the AAPS annual meeting in Florida this week. The event will give the firms a chance to start gathering feedback from outside of the select group of pharma customers and global partners that had advanced knowledge of the collaboration.

Feedback to date has been “extremely positive​”, Hanson said, and has led to orders for the product. “There are select successful installations in Europe, the U.S., and Asia with many more on the way​,” she said.

The next step is to drum up more interest in the testing system and then begin to get the product into the hands of customers. “We’re scheduled to begin shipping to customers in December after a few administrative details are finalised​,” Hanson said.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Content provided by Lonza Small Molecules | 28-Mar-2023 | White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Related suppliers

Follow us


View more